Pulmonary embolism · people hospitalised with COVID‐19
Higher‐dose anticoagulants probably leads to lower pulmonary embolism compared with lower‐dose anticoagulants (moderate certainty).
1 finding from 1 review
Major bleeding · people hospitalised with COVID‐19
Higher‐dose anticoagulants probably leads to higher major bleeding compared with lower‐dose anticoagulants (moderate certainty).
1 finding from 1 review
Adverse events (minor bleeding) · people hospitalised with COVID‐19
Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Eclampsia · women with pre‐eclampsia
1 finding from 1 review
Eclampsia: 2 g per hour IV maintenance versus 1 g per hour IV maintenance · women with pre‐eclampsia
1 finding from 1 review
Eclampsia: 2 g per hour IV versus weight‐adjusted maintenance dose · women with pre‐eclampsia
1 finding from 1 review
Severe morbidity · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects · women with pre‐eclampsia
Prevention of eclampsia: higher showed no clear difference in side effects compared with lower IV maintenance regimen (low certainty).
1 finding from 1 review
Death of baby (up to discharge) · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal death · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other neonatal morbidity · women with pre‐eclampsia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Re‐admission during · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in re‐admission in compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Asthma severity and symptoms · Adults with acute asthma
1 finding from 1 review
Asthma symptoms Complete resolution by day 28 · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in asthma symptoms Complete resolution by day 28 compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Exacerbations · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes new exacerbation in compared with lower dose/shorter course (very low certainty).
2 findings from 1 review
FEV1 % predicted · Adults with acute asthma
1 finding from 1 review
All adverse events · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes all adverse events compared with lower dose/shorter course (very low certainty).
1 finding from 1 review
300/450 IU vs 150 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 300/450 IU vs 150 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
400/450 IU vs 300 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in 400/450 IU vs 300 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review
IU vs 450 IU · women undergoing IVF/ICSI who are anticipated to have a low‐response to stimulation based on one or more ORT measure
Anticipated low responders: higher showed no clear difference in IU vs 450 IU compared with lower dose of FSH (low certainty).
1 finding from 1 review